Literature DB >> 22695035

Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations.

Paolo Curatolo1, Sergiusz Jóźwiak, Rima Nabbout.   

Abstract

Tuberous sclerosis complex (TSC) is a leading genetic cause of epilepsy. TSC-associated epilepsy generally begins during the first year of life, and is associated with neurodevelopmental and cognitive problems. Management is challenging and seizures tend to persist in a large proportion of patients despite pharmacological and surgical treatment. This report summarizes the clinical recommendations for the management of TSC-associated epilepsy made by a panel of European experts in March 2012. Current treatment options and outstanding questions are outlined.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695035     DOI: 10.1016/j.ejpn.2012.05.004

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  47 in total

1.  Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).

Authors:  Karin Mayer; Christa Fonatsch; Katharina Wimmer; Ans M W van den Ouweland; Anneke J A Maat-Kievit
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

2.  Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients.

Authors:  Flavio Giordano; Carla Moscheo; Matteo Lenge; Roberto Biagiotti; Francesco Mari; Iacopo Sardi; Anna Maria Buccoliero; Lorenzo Mongardi; Eleonora Aronica; Renzo Guerrini; Lorenzo Genitori
Journal:  Childs Nerv Syst       Date:  2019-12-18       Impact factor: 1.475

Review 3.  The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Authors:  Paolo Curatolo; Marit Bjørnvold; Patricia E Dill; José Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna Jansen; Sergiusz Jóźwiak; J Christopher Kingswood; Katarzyna Kotulska; Alfons Macaya; Romina Moavero; Rima Nabbout; Bernard A Zonnenberg
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

4.  Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.

Authors:  Marian E Williams; Deborah A Pearson; Jamie K Capal; Anna W Byars; Donna S Murray; Robin Kissinger; Sarah E O'Kelley; Ellen Hanson; Nicole M Bing; Bridget Kent; Joyce Y Wu; Hope Northrup; E Martina Bebin; Mustafa Sahin; Darcy Krueger
Journal:  Am Psychol       Date:  2019-04

Review 5.  Mechanism-based treatment in tuberous sclerosis complex.

Authors:  Kristina Jülich; Mustafa Sahin
Journal:  Pediatr Neurol       Date:  2013-12-05       Impact factor: 3.372

Review 6.  Infantile Spasms-Have We Made Progress?

Authors:  Sarah Aminoff Kelley; Kelly G Knupp
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-19       Impact factor: 5.081

Review 7.  Tuberous sclerosis complex: the past and the future.

Authors:  Liesbeth De Waele; Lieven Lagae; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2014-12-23       Impact factor: 3.714

8.  RNA Polymerase 1 Is Transiently Regulated by Seizures and Plays a Role in a Pharmacological Kindling Model of Epilepsy.

Authors:  Aruna Vashishta; Lukasz P Slomnicki; Maciej Pietrzak; Scott C Smith; Murali Kolikonda; Shivani P Naik; Rosanna Parlato; Michal Hetman
Journal:  Mol Neurobiol       Date:  2018-03-15       Impact factor: 5.590

Review 9.  A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Authors:  David M Feliciano; Tiffany V Lin; Nathaniel W Hartman; Christopher M Bartley; Cathryn Kubera; Lawrence Hsieh; Carlos Lafourcade; Rachel A O'Keefe; Angelique Bordey
Journal:  Int J Dev Neurosci       Date:  2013-02-26       Impact factor: 2.457

10.  Early neurodevelopmental screening in tuberous sclerosis complex: a potential window of opportunity.

Authors:  Tanjala T Gipson; Gwendolyn Gerner; Siddharth Srivastava; Andrea Poretti; Rebecca Vaurio; Adam Hartman; Michael V Johnston
Journal:  Pediatr Neurol       Date:  2014-05-04       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.